114 related articles for article (PubMed ID: 11016634)
1. Early resistance to therapy during induction in childhood acute lymphoblastic leukemia.
Brisco MJ; Sykes PJ; Dolman G; Hughes E; Neoh SH; Peng L; Snell LE; Toogood IR; Rice MS; Morley AA
Cancer Res; 2000 Sep; 60(18):5092-6. PubMed ID: 11016634
[TBL] [Abstract][Full Text] [Related]
2. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment.
Yamada M; Wasserman R; Lange B; Reichard BA; Womer RB; Rovera G
N Engl J Med; 1990 Aug; 323(7):448-55. PubMed ID: 2095753
[TBL] [Abstract][Full Text] [Related]
4. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
6. Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse.
Uckun FM; Gaynon PS; Stram DO; Sensel MG; Sarquis MB; Lazarus KH; Willoughby M
Clin Cancer Res; 1999 Sep; 5(9):2415-20. PubMed ID: 10499612
[TBL] [Abstract][Full Text] [Related]
7. [The clinical significance of MDR-1 gene expression in the hemopoietic cells of patients with acute leukemias in different phases of the disease].
Bykova TV; Sominskaia AA; Zaritskiĭ AIu; Stiuf IIu; Medvedeva BV; Anikina NA; Afanas'ev BV
Ter Arkh; 1998; 70(7):11-4. PubMed ID: 9742628
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
10. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
11. Late relapse of childhood acute lymphoblastic leukemia and pcr-monitoring of minimal residual disease: how much time can elapse between "molecular" and clinical relapse?
Aricò M; Germano G; del Giudice L; Ziino O; Locatelli F; Basso G
Haematologica; 2002 Apr; 87(4):ELT19. PubMed ID: 11940504
[No Abstract] [Full Text] [Related]
12. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
13. A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow.
Haddad G; Thorner PS; Bradley G; Dalton WS; Ling V; Chan HS
Lab Invest; 1994 Oct; 71(4):595-603. PubMed ID: 7967514
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
Oudot C; Auclerc MF; Levy V; Porcher R; Piguet C; Perel Y; Gandemer V; Debre M; Vermylen C; Pautard B; Berger C; Schmitt C; Leblanc T; Cayuela JM; Socie G; Michel G; Leverger G; Baruchel A
J Clin Oncol; 2008 Mar; 26(9):1496-503. PubMed ID: 18349402
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.
Rivera GK; Zhou Y; Hancock ML; Gajjar A; Rubnitz J; Ribeiro RC; Sandlund JT; Hudson M; Relling M; Evans WE; Pui CH
Cancer; 2005 Jan; 103(2):368-76. PubMed ID: 15599932
[TBL] [Abstract][Full Text] [Related]
16. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol.
Suzuki N; Yumura-Yagi K; Yoshida M; Hara J; Nishimura S; Kudoh T; Tawa A; Usami I; Tanizawa A; Hori H; Ito Y; Miyaji R; Oda M; Kato K; Hamamoto K; Osugi Y; Hashii Y; Nakahata T; Horibe K;
Pediatr Blood Cancer; 2010 Jan; 54(1):71-8. PubMed ID: 19813250
[TBL] [Abstract][Full Text] [Related]
17. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
18. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
Lönnerholm G; Thörn I; Sundström C; Frost BM; Abrahamsson J; Behrendtz M; Heldrup J; Jacobsson S; Li A; Olofsson T; Porwit A; Söderhäll S; Larsson R; Forestier E
Leuk Res; 2009 Jan; 33(1):46-53. PubMed ID: 18639340
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
20. Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy.
Moritz B; Eder J; Meister B; Heitger A
Med Pediatr Oncol; 2001 Feb; 36(2):283-9. PubMed ID: 11452936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
